Your 2026 Regulatory Readiness Blueprint for Life Sciences
Key Takeaways
A framework for self-assessing your regulatory readiness across QMSR, cGMP, and EU GMP — and how to spot the gaps inspectors are most likely to cite.
How to prioritize remediation based on inspection risk and your specific regulatory context, not just the length of a checklist.
A preview of the 90-day regulatory readiness sprint and what “audit-ready by design” looks like on a connected QMS platform.
Your 2026 Regulatory Readiness Blueprint for Life Sciences
Knowing the regulations changed is one thing. Knowing exactly what to do about it is another. 2026 has delivered more regulatory change to life sciences than any year in recent memory — QMSR harmonization took effect in February, the FDA published its first-ever Form 483 response guidance, Computer Software Assurance guidance was formalized, and the EU is finalizing sweeping updates to GMP Chapter 4 and Annexes 11 and 22. At the same time, remote assessments have normalized shorter-notice audits, and regulators are now using AI to inspect faster and find more. For quality leaders, the pressure is no longer whether to adapt, but how to do it systematically before an inspector finds the gap first.
This webinar cuts through the complexity with a practical, structured approach to regulatory readiness. We’ll walk through how to assess your compliance posture across QMSR, 21 CFR Parts 210–211, and EU GMP; how to prioritize remediation based on genuine inspection risk rather than checklist length; and how to preview the 90-day regulatory readiness sprint framework that moves organizations from reactive scrambling to always-on readiness. Throughout, we’ll show how MasterControl Quality Excellence (Qx) operationalizes each step — turning gap-closing into a capability that’s built into how you work every day, not bolted on before every audit.
Key Takeaways
A framework for self-assessing your regulatory readiness across QMSR, cGMP, and EU GMP — and how to spot the gaps inspectors are most likely to cite.
How to prioritize remediation based on inspection risk and your specific regulatory context, not just the length of a checklist.
A preview of the 90-day regulatory readiness sprint and what “audit-ready by design” looks like on a connected QMS platform.
Jessica Madsen
Senior Product Marketing Manager
MasterControl
Manufacturing, Quality, and Asset Management — Simplified with Life Sciences-Specialized AI.
Jessica is the Sr. Product Marketing Manager over MasterControl Quality Excellence. She has an extensive marketing career spanning nearly 20 years including leadership, strategy, product marketing, customer marketing, and demand gen. Jessica excels at working across teams to bring products to market and translating tech features to customer benefits that resonate.
Dave Hunter
Dave Hunter joined MasterControl in 2002. His extensive technology experience includes working for Microsoft, EDS, Intel, and TenFold for over 20 years. He received his bachelor’s degree in electrical engineering and his MBA from Brigham Young University. Reference: (1) The 483 observations and warning letter citations are related to document control subsystem as defined under the Quality System Regulation. The requirements can be found in 21 CFR Parts 820.40, 820.180, 820.181, 820.186, and 820.184. From “2014 Annual FDA Medical Device Quality System Data,” presented by the Center of Devices and Radiological Health (CDRH), FDA website.